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Abstract
Background: Myxoid liposarcoma is a relatively common malignant soft tissue tumor, characterized by a (12;16)
translocation resulting in a FUS-DDIT3 fusion gene playing a pivotal role in its tumorigenesis. Treatment options in
patients with inoperable or metastatic myxoid liposarcoma are relatively poor though being developed and new
hope is growing.
Results: Using kinome profiling and subsequent pathway analysis in two cell lines and four primary cultures of
myxoid liposarcomas, all of which demonstrated a FUS-DDIT3 fusion gene including one new fusion type, we
aimed at identifying new molecular targets for systemic treatment. Protein phosphorylation by activated kinases
was verified by Western Blot and cell viability was measured before and after treatment of the myxoid liposarcoma
cells with kinase inhibitors. We found kinases associated with the atypical nuclear factor-kappaB and Src pathways
to be the most active in myxoid liposarcoma. Inhibition of Src by the small molecule tyrosine kinase inhibitor
dasatinib showed only a mild effect on cell viability of myxoid liposarcoma cells. In contrast, inhibition of the
nuclear factor-kappaB pathway, which is regulated by the FUS-DDIT3 fusion product, in myxoid liposarcoma cells
using casein kinase 2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) showed a significant decrease in cell viability,
decreased phosphorylation of nuclear factor-kappaB pathway proteins, and caspase 3 mediated apoptosis.
Combination of dasatinib and TBB showed an enhanced effect.
Conclusion: Kinases associated with activation of the atypical nuclear factor-kappaB and the Src pathways are the
most active in myxoid liposarcoma in vitro and inhibition of nuclear factor-kappaB pathway activation by inhibiting
casein kinase 2 using TBB, of which the effect is enhanced by Src inhibition using dasatinib, offers new potential
therapeutic strategies for myxoid liposarcoma patients with advanced disease.
Background
Myxoid liposarcoma accounts for 40% of all liposarco-
mas and occurs most commonly in the extremities [1].
In about 95% of cases, myxoid liposarcoma is cytogen-
etically characterized by t(12;16)(q13;p11), creating a
chimerical FUS/DDIT3 gene which has been thought to
play a pivotal role in its tumourigenesis [2-4]. The cor-
nerstone of curative treatment for myxoid liposarcoma
is surgery with an overall 10 years survival of 80%. Prog-
nosis is mainly determined by the percentage of round
cell component of the tumor. Myxoid liposarcoma with
more than 5% round cell component are defined as
high-grade and prone to metastasis [5]. Treatment
options for patients with inoperable or metastatic dis-
ease are relatively poor, though trials with new drugs
reveal good perspectives for the future [6,7]. Therefore,
clinical trials to test and validate new treatment options
for liposarcoma subtypes (such as myxoid liposarcoma)
are necessary [6]. Nowadays, (neo) adjuvant chemother-
apy of liposarcoma patients is limited with only
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rates in untreated patients [8]. Trabectedin (Yondelis,
ET 743) is a novel chemotherapeutic agent derived from
the marine tunicate Ecteinascidia turbinate.B yb i n d i n g
to the DNA minor groove, ET-743 forms covalent
adducts with the N2-position of guanine through its car-
binolamine moiety. As a result, the minor groove bends
toward the major groove. The cytotoxic activity of ET-
743 is largely based on its interaction with nucleoside
excision repair machinery, as well as through the induc-
tion of double strand breaks [9-11]. Phase I and II stu-
dies showed promising results in myxoid liposarcoma
patients with advanced disease though recent studies
reported an increasing number of side effects [12,13].
During the last years, tumor specific targeted therapy
has shown to be effective in many cancers, including
sarcomas. Especially kinase inhibitors are an emerging
class of small molecule inhibitors that target unique
kinase conformational forms and binding sites [14].
Notable advantages are higher specificity and generally
more manageable and reversible side effects [15]. This
necessitates the study of separate soft tissue tumour
entities [7]. In the present study, we explored the acti-
vated pathways in myxoid liposarcoma cells using
kinome profiling to find new treatment possibilities.
Kinases phosphorylate tyrosine, threonine or serine resi-
dues on proteins, thereby serving as a switch to (in)
activate pathways involved in cell cycle, cell survival and
differentiation. Moreover, kinases are promising targets
for anti-cancer therapy as they do not require new pro-
tein synthesis, therefore act rapidly and are also promis-
ing in slow-cycling tumors [16,17].
Data on activated pathways in myxoid liposarcoma are
sparse [18,19]. By using a kinase substrate specific protein
array chip combining 1024 different kinase substrates, we
identified kinases associated with Src and NF-kappaB path-
ways to be active in myxoid liposarcoma. NF-kappaB is an
inducible cellular transcription factor that regulates a variety
of cellular genes, including those involved in immune regu-
lation, inflammation, cell survival and cell proliferation.
Hereby, active NF-kappaB plays a pivotal role in tumorigen-
esis and increased expression of the phosphorylated NF-kap-
paB protein is found in many tumors [20,21]. We showed
that in myxoid liposarcoma cells, inhibition of kinases asso-
ciated with the NF-kappaB pathway (by TBB) resulted in
decreased viability and that this effect was enhanced by Src-
inhibitor dasatinib. These results show that targeting NF-
kappaB pathway might be a potential treatment option in
myxoid liposarcoma patients with advanced disease.
Results
Molecular and cytogenetic analysis
FISH of the primary myxoid liposaromas showed
the tumor specific t(12;16) in three out of four cases
(table 1). All four primary cultures showed the FUS/
DDIT3 fusion transcripts [22]. Case L1187 showed a
1033 bp long fusion transcript involving exon 11 of the
FUS and exon 2 of the DDIT3 gene, which has not been
reported previously (figure 1). This chimera includes the
RNA-binding domain (exon 8-11) of the FUS gene as in
fusion type 8, which is absent in the other fusion types.
This new FUS/DDIT3 fusion type was deposited in Gen-
Bank (GenBank accession number GU933437). COBRA-
FISH of both myxoid liposarcoma cell lines showed the
myxoid liposarcoma specific t(12;16) translocation. The
precise karyotype of 402-91 was: 46, X, der(Y)t(Y;19)
(q11;p11), t(1;7)(p12;p12), der(8)t(8;21)(p11;p11) [7], der
(8)t(8;9)(p11;p11) [7], del(8)(p11) [4], del(10)(p11),
t(12;16)(q13;p11), del(18)(p11), -19,+20, -21 [7] [cp20],
several additional, non-clonal rearrangements involving
chromosomes 4, 5, 6 and 8 with various partner chro-
mosomes. The precise karyotype of 1765-92 was 90-99,
XX, der(1)inv(1)(p32q31)t(1;10)(p33;p12), der(1)inv(1)
(p32q31)t(1;10) (p33;p12), -1, del(2)(p11), -3, +5, der(6)t
(4;6)(4q, 6q), der(6)t(6;10)(p;q), +der(6)t(6;10) (p;q), der
(8)t(3;8), i(8)(q10), +i(8)(q10), +9, der(10)t(1;10)(1p32,
p12), der(10)t(1;10) (1p32, p12), -10, +11, t(12;16)(q13;
p11), t(12;16)(q13;p11), -13, der(13)t(6;13)(q;q), +14,
+15, +18, +20, +20 [cp20].
Identification of active kinases and pathways
A list of phosphorylated targets and their corresponding
active kinases was created by kinome profiling of two
cell lines and four primary cultures of myxoid liposar-
coma. Average spot intensity and target frequency of the
top 100 phosphorylated substrates revealed the most
activated kinases in myxoid liposarcoma (table 2). Both
in myxoid liposarcoma cell lines as well as in primary
cultures, casein kinase 2, alpha 1 (ck2a1), lymphocyte-
specific protein tyrosine kinase (lck), fyn oncogene
related to SRC (fyn), Gardner-Rasheed feline sarcoma
viral (v-fgr) oncogene homolog (fgr), v-yes-1 Yamaguchi
sarcoma viral oncogene homolog (yes), calcium/calmo-
dulin-dependent protein kinase II beta (camk2b) and
protein kinase, cAMP-dependent, catalytic, alpha
(prkaca) were most activated (table 2). There were no
clear differences between the cell lines and the primary
cultures. The specificity of the list of substrates for myx-
oid liposarcomas was verified by comparing the intensity
of the signals with those for normal MSCs which served
as a normal control for this tumor type, using Limma
(additional file 1). Specificity of the activated kinases in
this type of cancer (i.e. myxoid liposarcoma) was addi-
tionally verified by comparison with the same analysis in
four colorectal carcinoma cell lines and thirteen chon-
drosarcoma cell lines and cultures using Limma, which
revealed a different list of substrates and kinases [16].
Pathway analysis based on the most active kinases
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pathway (ck2a1, fgr, inhibitor of kappa light polypeptide
gene enhancer in B-cells, kinase (ikk), protein kinase
RNA-activated (pkr), v-akt murine thymoma viral onco-
gene homolog (akt), NF-kappa-beta-inducing kinase
(nik), mitogen-activated protein kinase kinase kinase 3
(mekk3) and focal adhesion kinase 1 (fak1) to be most
activated. Also kinases associated with Src-pathway (lck,
fyn) were highly active. In addition, retinoic acid recep-
tor pathway (RAR) and peroxisome proliferator-acti-
vated receptor (PPAR) activation pathway were found.
The top 5 of activated pathways was identical in cell
lines and primary cultures. Results of the analysis leav-
ing out all cell cycle related kinases (27% of all kinases
detectable), which might be artificially upregulated due
to cell culturing, and results of analysis after starvation
of the cell lines are shown in table 3.
Verification of kinome profiling
Western blotting showed that all myxoid liposarcoma
samples (both cell lines and primary cultures) expressed
comparable amounts of total Src and NF-kappaB p65.
Phosphorylation of Src (Y419) was present in all sam-
ples (figure 2) confirming activation of Src pathway.
Likewise, western blotting showed the presence of ck2a1
and phosphorylated NF-kappaB p65 (S468) in all sam-
ples, confirming the results of the IPA analysis that
kinases associated with NF-kappaB pathway are active in
myxoid liposarcoma cells.
In vitro targeting of kinases associated with Src and
NF-kappaB pathways by dasatinib and TBB
WST-1 analysis of GIST882 showed a profound
decrease in cell viability of up to ~ 80% relative to the
DMSO control at even low dosages of Src-inhibitor
dasatinib (figure 3). The decrease in cell viability of
myxoid liposarcoma cells treated with dasatinib was
rather mild as WST-1 analysis of all four cell cultures
and 1 out of 2 cell lines showed a maximum decrease in
cell viability of 40% at higher doses (figure 3). Cell line
1765-92 did not respond to dasatinib. In contrast, myx-
oid liposarcoma cells showed a decline of more than
50% in viability after treatment with casein kinase
2-inhibitor TBB in two out of four cultures and in both
cell lines. This effect was also observed in Jurkat cells as
described (positive control) [23]. There was no relation
between the response rate and type of fusion gene. For
combination experiments, the two cell lines (402-91 and
1765-92) and the two most sensitive myxoid liposar-
coma primary cultures (L1357 and L2187) were treated
with both dasatinib and TBB. Combined administration
of both drugs led to a dramatic decrease in cell viability
and showed an enhanced effect (figure 3D), for instance:
Table 1 Clinicopathological and genetic data of myxoid liposarcoma samples
Sample
ID
Type Gender Age P/R/M Location FUS/DDIT3 transcript
size
FUS/DDIT3 transcript
type
(COBRA)
FISH
1 L1187 primary
culture
F 20 P left hamstrings 1033 bp X t(12;16)
2 L1357 primary
culture
M 50 P left hamstrings 654 bp I t(12;16)
3 L1434 primary
culture
F 43 P right hamstrings 654 bp I t(12;16)
4 L2187 primary
culture
F 42 P left thigh,
subcutaneously
378 bp II N/A
5 402-91 cell line M unknown unknown unknown unknown N/A t(12;16)
6 1765-92 cell line unknown unknown unknown unknown unknown N/A t(12;16)
Primary cultures of samples L1187, L1357, L1434 and L2187 were obtained from fresh tumors. Tumors L1187 and L1357 were high grade (> 5% round cell
component), whereas L1434 and L2187 were low-grade (< 5% round cell component). These differences in grade however were not reflected in growth rate of
the primary cultures (doubling times of primary cultures were all ~ 4 days; doubling times of cell lines ~ 2 days).
protein
SYQG - rich region RGG - rich region RNA -binding
DDIT3 gene (part. exon 2) 5’ 3’ FUS gene (part. exon 11)
G C G A  G   G  A  G   T G T   T C A  A G   A   A G
protein
SYQG - RGG - RNA -
G  G    C G G   G  A  G   T G  A  A G    G
domain
mRNA mRNA
FUS DDIT3
Leucine zipper dimerization domain DNA binding domain
387 391 390 392 388 389 393
Figure 1 Exon 11 of the FUS gene is fused to exon 2 of the
DDIT3 gene. The corresponding chimeric protein retains the RNA
binding domain of the FUS protein.
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dose (5000 nM), whereas viability was only 5% at lower
concentration of dasatini b( 5 0 0n M )a tI C5 0f o rT B B
(figure 3D).
Dasatinib inhibits phosphorylation of Src but does not
cause apoptosis
To investigate the effect of dasatinib on Src signalling, a
good responsive (60% cell viability at 500 nM; figure
3A) myxoid liposarcoma cell culture (L1357) was treated
with 50, 200 and 500 nM of dasatinib for 6 hours.
Whereas levels of total Src did not visibly decrease upon
dasatinib treatment, a decrease in phosphorylated Src
(p-Src) (Y419) was found (figure 4). At a dose of
200 nM dasatinib p-Src staining the lower band faded
and at 500 nM both bands disappeared. Interestingly, a
similar decrease in p-Src was also observed at 200 nM
dasatinib when post-treated with TBB. There was no
effect of dasatinib treatment on total NF-kappaB p65
or phosphorylated NF-kappaB p65 and there was no
Table 2 Top 100 activated kinases and targeted drugs in myxoid liposarcoma cell lines and primary cultures
Intensity Kinase Number of hits Description Drugs
1 7965,340 CK2 9 Casein kinase 2, alpha 1 4,5,6,7-tetrabromobenzotriazole
2 5932,666 LCK 3 Lymphocyte-specific protein tyrosine kinase dasatinib
3 5932,666 FYN 2 FYN oncogene related to SRC, FGR, YES dasatinib
4 4716,473 CAMK2B 5 Calcium/calmodulin-dependent protein kinase II beta
5 3998,331 PRKACA 8 Protein kinase, cAMP-dependent, catalytic, alpha
6 3922,920 MAPK1 4 Mitogen-activated protein kinase 1
7 3922,920 KIT 1 V-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog dasatinib, sunitinib ao
8 3402,973 CSNK1A1 1 Casein kinase 1, alpha 1
9 3402,973 CIB 2 Calcium and integrin binding family
10 3317,951 GSK3 2 Glycogen synthase kinase 3
11 3144,082 LYN 1 V-yes-1 Yamaguchi sarcoma viral related oncogene homolog
12 3144,082 BTK 1 Bruton agammaglobulinemia tyrosine kinase
13 3114,907 PKC 19 Protein kinase C
14 3057,647 AKT1 3 V-akt murine thymoma viral oncogene homolog 1 enzastaurin
15 3033,443 PKM2 1 Pyruvate kinase, muscle
16 2928,117 CAMK1 1 Calcium/calmodulin-dependent protein kinase I
17 2893,922 CHEK1 1 CHK1 checkpoint homolog
18 2893,922 CHEK2 2 CHK2 checkpoint homolog
19 2893,922 PLK3 2 Polo-like kinase 3
20 2890,210 TTN 1 Titin
21 2712,053 ABL 2 Abelson murine leukemia viral (v-abl) oncogene homolog imatinib, temozolomide
22 2596,825 INSR 1 Insulin receptor lispro, aspart, glargine
23 2596,825 EGFR 2 Epidermal growth factor receptor cetuximab, canertinib ao
24 2596,825 MET 1 Met proto-oncogene
25 2483,173 SRC 6 V-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog
26 2443,714 RPS6 4 Ribosomal protein S6
27 2382,003 CK 1 Choline kinase
28 2314,823 MAP2K3 1 Mitogen-activated protein kinase kinase 3
29 2294,228 GRK1 2 G protein-coupled receptor kinase 1
31 2216,637 JAK1 1 Janus kinase 1
32 2214,443 MAPKAPK2 1 Mitogen-activated protein kinase-activated protein kinase 2
33 2179,345 ALK 1 Anaplastic lymphoma receptor tyrosine kinase
34 2052,700 ATM 2 Ataxia telangiectasia mutated
35 2040,371 PKN1 2 Protein kinase N1
36 1913,813 PDGFRB 1 Platelet-derived growth factor receptor, beta polypeptide dasatinib, sunitib ao
37 1870,956 CDK2 1 Cyclin-dependent kinase 2 BMS-387032, flavopiridol
38 1849,628 CCRK 1 Cell cycle related kinase
39 1806,824 CDC2 1 Cell division cycle 2, G1 to S and G2 to M flavopiridol
Top list of kinases was based on the intensity of incorporated radioactively labeled phosphorus, corresponding with kinase activity. The number of hits
corresponds to the number of substrates to be phosphorylated by a specific kinase, not necessarily associated with kinase activity as substrates were not equally
covered by the different kinases.
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3 did not increase upon dasatinib treatment (figure 4).
TBB inhibits NF-kappaB p65-phosphorylation resulting in
caspase-3 mediated apoptosis
To investigate the effect of TBB on kinases associated
with NF-kappaB signalling, L1357 was treated with
increasing doses for 6 hours. Whereas levels of total
NF-kappaB p65 did not decrease upon treatment, a
decrease in phosphorylated p65 (p-p65) was found (fig-
u r e4 ) .A tad o s eo f2 0μM TBB p-p65 staining slightly
started to fade and obviously decreased at 200 μM TBB.
Casein Kinase 2 levels of TBB treated samples were
lower than the DMSO control, but remained unchanged
compared to samples treated with various concentra-
tions TBB or dasatinib, suggesting that TBB does not
alter the overall expression of casein Kinase 2, which is
in accordance with the literature [24]. TBB treatment
h a dn oe f f e c to nt h el e v e l so ftotal Src and phosphory-
lated Src. Strikingly, the effect of TBB was increased by
pretreatment with dasatinib (figure 4), which was also
visible in the viability assay (figure 3D). Moreover, there
was a gradual increase in caspase-3 levels upon treat-
ment with TBB, suggesting caspase-3 mediated
apoptosis.
Discussion
Treatment options for myxoid liposarcoma patients with
advanced disease are poor. Recently, the chemothera-
peutic drug Trabectedin showed promising results in
phase I and II trials in advanced disease though adverse
effects have also been reported [13,25]. Small molecule
targeting, especially with kinase inhibitors, has shown to
be effective and more specific in many tumors with less
severe side effects than conventional chemotherapeutic
agents. To identify new potential treatment options for
myxoid liposarcoma patients with advanced disease, we
explored the kinome of myxoid liposarcoma cells
in vitro and performed subsequent pathway analysis.
We previously established the reliability of kinome
profiling using Pepchip in untreated versus imatinib
treated GIST882 cell line which correctly identified the
Table 3 Top lists of activated kinases and pathways in different conditions
top five activated kinases top activated signalling pathway
normal medium condition (including all kinases in the analysis) ck2a1 NF-kappaB
lck Src
fyn RAR
fgr PPAR
yes
normal medium condition (leaving out cell cycle related kinases in the analysis) ck2a1 NF-kappaB
lck Src
fyn RAR
camk2b PPAR
prkcd
starved medium condition mapk14 NF-kappaB
ck2a1 RAR
akt1 p53
egfr G1/S transition of the cell cycle
erbb2 oxidative stress response
Whereas activated kinases differed between cells grown in normal medium (RMPI supplemented with 10% inactivated calf serum), top five of activated signaling
pathways were identical. Results were identical for cell lines and primary cultures. Cell lines cultured in starved medium conditions revealed a different top list of
both kinases and activated signaling pathways. However, in all three different conditions, NF-kappaB was the most activated signaling pathway identified.
prkcd: protein kinase C, delta; mapk14: mitogen-activated protein kinase 14; egfr: epidermal growth factor receptor; erbb2: v-erb-b2 erythroblastic leukemia viral
oncogene homolog 2.
Figure 2 Immunoblotting was used for verification of the
results obtained by Pepchip analysis. Band heights were all
corresponding to the manufacturer’s datasheets (P-Src: 2 bands
between 56-61 kDa, Src: 60 kDa, Casein Kinase 2: 42 kDa, P-p65: 65
kDa and p65: 65 kDa). Both cell lines and primary cultures showed
phosphorylation of Src and slight variation in amounts of total Src.
Casein Kinase 2 and p65 protein were present in all samples in
comparable amounts, as is phosphorylated p65, indicating active
NF-kappaB signaling.
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Page 5 of 12pathways known to be involved in GIST [16]. Moreover,
we previously demonstrated the reliability of our analy-
sis which is based on averaging results of a number of
samples to get an impression of the most activated
kinases in a series of tumors [16]. By additionally per-
forming the Pepchip experiments in the myxoid liposar-
comas cell lines after serum starvation as well as by
excluding cell cycle related kinases from the analysis we
determined that the detected kinases in the present ana-
lysis are indeed tumor specific and not related to the
high proliferation rate of the myxoid liposarcoma cell
lines. Moreover, by comparing with previously analyzed
series of colorectal cancer and chondrosarcoma, as well
as by comparing with mesenchymal stem cells we could
confirm that the list of kinases was specific for myxoid
liposarcomas.
We could demonstrate activation of the peroxisome
proliferator-activated receptor gamma pathway, which
could be expected since it has been shown to play a
pivotal role in adipocytic differentiation and is regulated
by the FUS-DDIT3 fusion product [26-28](Figure 5).
The DDIT3 gene encodes a DNA-damage inducible
member of the C/EBP family of transcription factors
and inhibits adipocytic conversion of preadipocytes
[29,30]. Transfection of primary mesenchymal progeni-
tor and human fibrosarcoma cells with the FUS/DDIT3
fusion protein induces a myxoid liposarcoma phenotype
[31,32]. Treatment of myxoid liposarcoma cells in vitro
and in vivo with peroxisome proliferator-activated
receptors gamma agonists induced terminal differentia-
tion [33], although phase II studies with the peroxisome
proliferator-activated receptors gamma agonist Rosiglita-
sone did not show the antitumor effect in advanced
myxoid liposarcoma patients [34]. Until today, nine dif-
ferent types of FUS/DDIT3 fusion genes have been
described, involving predominantly the central and C-
terminal parts of the FUS-gene and nearly always the
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Figure 3 Effect of dasatinib and TBB treatment on cell viability of myxoid liposarcoma cells. 3A) Treatment of myxoid liposarcoma cell
cultures with dasatinib leads to maximum 20% decrease in viability at the concentrations higher than 200 nM, though this effect is limited as
compared to GIST882. 3B) Treatment with TBB shows a 20% decrease at lower concentrations (20 μM) and a maximum decrease of 75% at
200 μM (cell line 402-92) in the majority of cases. Cell viability with IC50 s as depicted in 3C. 3D) Combined treatment with TBB (at IC50
concentration) and dasatinib (concentrations as in 3A). Jurkat cells where susceptible to TBB, but not to dasatinib. Interestingly, the effect of
dasatinib when preceded by TBB was significantly more pronounced than dasatinib in monodrug treatment which means that dasatinib and
TBB have an enhanced effect. Graphs show data from four representative experiments. Error bars indicate the standard error of the mean.
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binding domain of the FUS gene, which is not found in
the other fusion types except for type 8. Whether this
new rare fusion gene will be translated to a protein or
will have any promoting effect on tumor development is
not clear and is hard to study due to the rarity of these
variants. We found no differences between the type of
FUS/DDIT3 fusion gene and kinases activated. Till now,
the molecular variability of fusion types has not shown
to have any effect on transforming capacities, adipogen-
esis nor prognosis in myxoid liposarcoma [5,35].
We showed that kinases associated with NF-kappaB
pathway were highly active in myxoid liposarcoma. In
the atypical (IKK independent) NF-kappaB pathway,
phosphorylation of inhibitors of NF-kappaB (IkB), and
subsequent activation of NF-kappaB (p65) is controlled
by casein kinase 2 and tyrosine kinase-dependent path-
ways (figure 5) [36,37]. We did not measure NF-kappaB
pathway activation by analysis of downstream products
or electrophoretic mobility shift assays. Göransson et al.
has recently shown that NF-kappaB is a major factor
controlling IL8 transcription in FUS-DDIT3 expressing
cells. This could be explained by direct binding of FUS/
DDIT3 to the C/EBP-NF-kappaB composite site of the
immediate promoter region of IL8. Moreover, FUS/
DDIT3-GFP expressing cell lines showed upregulation
of the NF-kappaB controlled genes LCN2 and MMP1
whereas DDIT3 had little effect. These findings were
also quantitatively confirmed by RT-PCR [17]. Active
(phosphorylated) p65 was present in cell lysates of myx-
oid liposarcoma cell cultures and cell lines. We did not
explicitly show that the phosphorylated p65 protein was
located in the nucleus/nuclear fraction. Phosphorylation
of p65 could be counteracted by TBB, an inhibitor of
the casein kinase 2 and resulted in decreased cell viabi-
lity as shown in figure 3 and 4. This suggests that NF-
kappaB signaling is active in myxoid liposarcoma and
that its activation is, at least in part, regulated via the
atypical pathway. This is an important finding which
suggests that NF-kappaB pathway inhibition might be
beneficial in myxoid liposarcoma patients with advanced
disease.
The exact driving force behind NF-kappaB activation
in myxoid liposarcoma is unclear. Gene expression stu-
dies revealed that p50 was significantly upregulated in
FUS/DDIT3 transfected fibroblastic cell lines [38]. This
suggests that NF-kappaB (p50) transcription in myxoid
liposarcoma might be regulated by the FUS/DDIT3
fusion gene. After translocation to the nucleus, tran-
scriptional activation of NF-kappaB requires multiple
co-activating proteins [39]. The C-terminus of FUS co-
activates p65 and plays a pivotal role in NF-kappaB
mediated transcription though this C-terminus is lost in
the FUS/DDIT3 fusion protein. Recent studies showed
that the FUS/DDIT3 fusion protein facilitates NF-kap-
paB binding to its target genes, probably in an indirect
manner [19,39-41]. The FUS-DDIT3 fusion protein
deregulates NF-kappaB controlled genes by interaction
with nuclear factor of kappa light polypeptide gene
enhancer in B-cells inhibitor zeta (NFKBIZ) [19]. This
synergistic role between a fusion protein and activation
of NF-kappaB signaling might also be important in
other translocation based sarcomas and has already
been shown in Bcr-Abl mediated leukemias [42].
In all myxoid liposarcoma samples we showed overex-
pression of casein kinase 2, which has been shown in
many other neoplasms [43]. We showed inhibition of
casein kinase 2 and subsequent decreased levels of active
p65 to be associated with decreased viability and
increase in caspase 3 protein expression in myxoid lipo-
sarcoma cells. Caspase 3 is released by cleavage of its
inactive precursor procaspase 3, and mediates apoptosis
[44,45]. Decreased cell viability with increased levels of
the effector caspase 3 therefore suggests caspase 3
mediated apoptosis. Recently, phase I trials have been
started to test the effect of casein kinase 2 inhibitors
in vivo which seems to be promising [46].
Figure 4 Effect of dasatinib and TBB treatment on
phosphorylation of Src and NF-kappaB related proteins.
Experiments were run in duplicate and showed similar results in
two cell lines (402-91 and 1765-92) and primary cultures (L1357 and
L2187). Treatment of L1357 with dasatinib did not affect total levels
of Src, but gradually decreased P-Src levels at 200 nM to almost
absence at 500 nM. There was no effect of dasatinib on total p65
and phosphorylated-p65 levels. Treatment of L1357 with TBB did
not affect total levels of p65, but gradually decreased P-p65 levels at
200 μM. TBB treatment had no effect on the levels of total Src and
phosphorylated Src. Interestingly, TBB and dasatinib showed
enhancement to decrease levels of phosphorylated Src and p65.
Strikingly, there was a gradual increase in caspase-3 levels upon
treatment with TBB, which was enhanced by combination with
dasatinib, suggesting caspase-3 mediated apoptosis underlying the
observed decrease in cell viability. Abbreviations: DAS50 = dastinib
50 nM, etc. DAS and TBB = 200 μM dasatinib and IC50
concentration for TBB.
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Page 7 of 12In addition to kinases associated with NF-kappaB, Fyn,
Lck and Yes were most active as indicated by specific
sequences on the chip. They are members of the Src
family of kinases. Src plays an important role in embryo-
nic development, cell growth and cell survival and acti-
vating mutations in Src have been reported in colorectal
carcinoma [47,48]. Src signaling can lead to downstream
activation of ERK/MAPK and PI3K/AKT signaling. Acti-
vation of both pathways in myxoid liposarcoma is asso-
ciated with more aggressive behavior [49]. The Src
pathway can be inhibited by the small molecule tyrosine
kinase inhibitor dasatinib limiting cell growth in various
cancers in vitro, thereby having promising therapeutic
potential [16,50,51]. Immunoblotting confirmed the
expression of Src and phosphorylation of Src at Y419 in
myxoid liposarcoma cell cultures and cell lines. Dasatinib
treatment showed a reduction in phosphorylated (active)
Src and a decrease in cell viability. However, this latter
effect was only very mild with maximum decrease in via-
bility of only 40% maximally, and no IC50 levels could be
calculated. This might be explained by Src pathway acti-
vation occurring upstream, close to its receptor (figure 5)
and that the effect of the inhibition of Src phosphoryla-
tion might be (partly) circumvented by crosstalk activa-
tion downstream. Our data suggest that the active Src
pathway is not crucial for myxoid liposarcoma survival
and that monotherapy with dasatinib is no suitable
option for treatment, although the additional effect of
dasatinib in vivo through inhibition of angiogenesis is not
encountered here.
Combinations of different drugs (including dasatinib)
have been shown to act synergistically in many tumors
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Figure 5 In myxoid liposarcoma, the FUS/DDIT3 protein has been shown to upregulate the expression of CCAAT/enhancer binding
protein (C/EBP) which leads to the transcription of peroxisome proliferator-activated receptors gamma and other genes involved in
adipocytic differentiation. We showed that in myxoid liposarcoma, the atypical NF-kappaB pathway is active. Hereby casein kinase 2
phosphorylates the nuclear factor of kappa light polypeptide gene enhancer in B-cells inhibitor (IkB), which releases from the NF-kappaB p50/
p65 complex and gets degraded. The NF-kappaB p50/p65 complex then shuttles into the nucleus were it promotes the transcription of genes
involved in cell proliferation. Recent studies showed that the FUS/DDIT3 protein facilitates DNA binding of the NF-kappaB p50/p65 complex in a
non-direct manner, probably by interfering with IkB. Also Src pathway is activated in myxoid liposarcoma, which leads through different
signaling pathways (AKT, MEK, ERK) to tumor growth and cell survival. This pathway can be inhibited in vitro by Src-inhibitor dasatinib.
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cer treatment [50]. Recently, a synergistic effect of dasati-
nib when combined with other drugs (i.e. oxaliplatin) has
been described in colorectal carcinoma [50]. Since we
showed NF-kappaB and Src to be the two most active
pathways we studied the effect of combination of dasati-
nib and TBB and we found a enhanced effect on cell via-
bility of myxoid liposarcoma cells in vitro.T ob em o r e
specific: L1357 cells show 80% viability at maximum
dasatinib dose (5000 nM), whereas viability was only 5%
at lower concentration of dasatinib (500 nM) at IC50 for
TBB (figure 3). However, it was not possible to calculate
if this enhancement was also a true synergistic effect as
IC50 values for dasatinib could not be calculated (figure
3) [52]. IC50 values for TBB (but not for dasatinib) could
be calculated for most primary cultures and cell lines, but
not for L1187 and L1434. Though cell line 1765-92
responded well to TBB treatment, no enhancement could
be observed upon addition of dasatinib, which might be
related to a relative resistance of 1765-92 cells to dasati-
nib as also visible from figure 3A. Future experiments,
for instance studying the changes at the kinome level
upon dasatinib treatment may reveal (1) why dasatinib is
not effective as a monotherapy but is effective in combi-
nation with TBB, and (2) what might be the exact under-
lying mechanism why 1765-92 myxoid liposarcoma cells
showed resistance for dasatinib treatment and thereby
the absence of enhancement in combination treatment as
was observed for the other cell line and primary cultures.
Conclusion
In conclusion our results indicate that the NF-kappaB
and Src pathway include the most active kinases in myx-
oid liposarcoma, and inhibition of casein kinase 2 and
thereby interference with kinases associated with the
NF-kappaB pathway decreases cell viability in vitro,t h e
effect of which can be enhanced by inhibiting src- sig-
nalling using dasatinib.
Methods
Reagents
Dasatinib (Sprycel, BMS- 354825) was obtained from
Bristol-Myers Squibb (New York, USA) and TBB from
Calbiochem (San Diego, CA). Both drugs were dissolved
in Dimethylsulfoxide (DMSO).
Cell cultures and cell lines
T h et w om y x o i dl i p o s a r c o m ac e l ll i n e s4 0 2 - 9 1a n d
1765-92, and gastro-intestinal stroma cell tumor cell
line (GIST882) were kindly provided by Prof. Dr.
P. Aman (Lundberg Laboratory for Cancer Research,
Department of Pathology, Göteborg University, Gote-
b u r g ,S w e d e n )a n dP r o f .D r .J .F l e t c h e r( B r i g h a ma n d
Women’s Hospital, Boston, USA) respectively [53,54].
Jurkat and HeLa cell lines (American Type Culture Col-
lection, Rockville, MD) were used as positive controls
for Western blotting. Myxoid liposarcoma cell lines, pri-
mary cultures of four myxoid liposarcomas (L1187,
L1357, L1434 and L2187) and two cell cultures of nor-
mal bone marrow derived mesenchymal stem cells
(L2361 and L2370) were cultured in RPMI 1640 (Gibco,
Invitrogen Life-Technologies, Scotland, UK), supplemen-
ted with 10% heat-inactivated fetal calf serum (Gibco).
Cells were grown in a humidified incubator at 37°C with
5% CO2. In addition, two samples (402-19 and L1357)
were analyzed after also culturing in starved RPMI 1640,
containing 0,5% fetal calf serum.
RT-PCR and karyotyping
Diagnosis of the primary tumors from which the cul-
tures were obtained was performed on histology. Pri-
mary tumors were analyzed for their tumor specific
translocation with double-fusion fluorescence in situ
hybridization (FISH) and cell lines were karyotyped with
Combined Binary Ratio Labeling (COBRA) as previously
described [55-57]. In primary cultures, tumor cells were
genotyped for the presence of the fusion gene by RT-
PCR. Total RNA was isolated using TRIzol (Invitrogen,
Breda, The Netherlands). Complementary DNA was
synthesized from 1 μgo ft o t a lR N Au s i n go l i g od Tp r i -
mers and Superscript II MMLV reverse transcriptase
(Life Technologies, Carlsbad, CA). Reverse-transcription
polymerase chain reaction (RT-PCR), sample purifica-
tion and DNA sequence analysis were performed as
described previously [58]. The following primers were
used: FUS-forward, CAG AGC TCC CAA TCG TCT
TAC GG and DDIT3-reverse, GAG AAA GGC AAT
GAC TCA GCT GCC.
Kinome array analysis
Kinase substrate peptide arrays (Pepchip Kinomics,
Pepscan Presto, Lelystad, the Netherlands) containing
1024 different kinase substrates spotted in triplicate
together with 16 negative, and 16 positive controls
were used and successfully used in prior studies
[16,59]. The distribution of the target sequences in
terms of kinase recognition is described in detail on
the website http://www.pepscanpresto.com/index.php?
id=30. Cells were harvested during their exponential
growth phase and lysated as previously described. Con-
centration of the protein lysates was measured using
the DC Protein Assay (Biorad, Hercules, CA, USA).
Analysis was performed as described earlier, including
the two serum-starved samples [16]. Autoradiographic
signals were sensed by phosphoimage screen and
scanned by Typhoon 9400 phosphoimager (GE Health-
care, Piscataway, NJ). At least 1 × 10
6 hits were
collected.
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The scanned images were analyzed and quantified using
ImageQuant software (Molecular Dynamics, Sunnyvale,
CA). For further data mining R-packages Affyio and
Limma were used http://www.bioconductor.org. Quality
of the triplicates and distribution of the data was
assessed and quartile normalization (Affyio) was per-
formed as previously described [16]. Median intensities
of the triplicates were calculated and the top 100 spots
were imported for core analysis in Ingenuity Pathway
Analysis (IPA, Ingenuity Systems, http://www.ingenuity.
com). IPA is a literature based program that calculates
the probability of involvement of identifiers, in this case
combinations of kinases, in 74 different pathways. Data
of the myxoid liposarcoma cell lines and cultures were
averaged to find the common denominators that are
active in all cultures [16]. To ensure that artificially
induced kinase activity due to cell culturing interfered
with tumor specific kinase activity, the same analysis
was run excluding cell cycle related kinases as well as
after starvation. Specificity of activated kinases and acti-
vated pathways in myxoid liposarcoma was verified by
comparison the same analysis of four colorectal carci-
noma cell lines and thirteen chondrosarcoma cell lines
and cultures using Limma [16].
Immunoblotting
Western blotting was performed as previously described
[58]. Rabbit polyclonal antibody to phosphorylated Src
(Y419) was obtained from R&D Systems (1/2000; Min-
neapolis, MN USA). Monoclonal antibody to total Src
and alpha-tubulin were obtained from Upstate Biotech-
nology (clone GD11, 1/2000, Lake Placid, NY, USA) and
Sigma Aldrich (St. Louise, MO, USA), respectively. Rab-
bit polyclonal antibodies against casein kinase 2alpha;
NF-kappaB p65, phospho- NF-kappaB p65 (S468) and
caspase 3 were obtained from Cell Signaling Technology
(Beverly, MA). HeLa cell lines, untreated and treated
with TNFalpha (20 ng/ml) were used as a positive con-
trol for casein kinase 2alpha and NF-kappaB p65/phos-
pho- NF-kappaB p65, respectively, according to the
manufacturer’s protocol.
In vitro viability assays
Measurement of metabolic activity by a WST-1 colori-
metric assay (Roche Diagnostics GmbH, Penzberg, Ger-
many) was used as a read-out system for cell viability in
response to kinase inhibitors. Dasatinib was used to
inhibit Src-pathway; TBB was used to inhibit casein
kinase 2, which is an important kinase in atypical NF-
kappaB signalling. After harvesting, 2000 cells/well of
every cell line and primary culture were seeded into 96-
well flat-bottom plates. After 24 hours, increasing
concentrations of the drugs (50, 100, 200, 500, 1000 and
5000 nM for dasatinib and 10, 20, 50, 100, 200 and
500 μM for TBB respectively) were added or 0,1%
DMSO as vehicle control, each condition in quadrupli-
cate. Ten percent serum supplementation was used for
all experiments. After 3 days of treatment, absorbance
was measured on a Victor Multilabel Counter 1420-042
(Perkin Elmer, Groningen, The Netherlands) at 450 nm,
and was corrected for background and averaged.
GIST882 and Jurkat cell lines were used as positive con-
trols for dasatinib and TBB experiments, respectively
[16]y. In combination experiments, 2000 cells were pla-
ted overnight followed by treatment with dasatinib
which was added 30 minutes after TBB administration.
In these experiments, increasing concentrations of dasa-
tinib at IC50 concentrations of TBB were used.
Additional material
Additional file 1: Top 100 of activated kinases in MSCs obtained by
kinome analysis. Table shows list of kinases found to be activated in
mesenchymal stem cells, in decreasing order. The intensity correlates
with the radioactivity of
33P incorporated in the substrates by their active
kinases. The number of hits are the number of substrates related to the
respective kinase.
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